Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections

Keyphrases

• Biofilm Infection 100%
• Nanotechnology 100%
• Pharmaceutical Strategies 100%
• Tightly Bound Extracellular Polymeric Substances (TB-EPS) 33%
• Difficult-to-treat 16%
• Treatment Strategy 16%
• Antibiotics 16%
• Clinical Treatment 16%
• Recent Advances 16%
• Biofilm 16%
• Biofilm Formation 16%
• Respiratory Infection 16%
• Antimicrobial Therapy 16%
• Clinical Approach 16%
• Global Health Issue 16%
• Surgical Removal 16%
• Environmental DNA (eDNA) 16%
• Biofilm Structure 16%
• Drug Delivery System 16%
• Drug Penetration 16%
• Antibiotic Combination 16%
• Airway mucus 16%
• Inhaled Antibiotics 16%
• Delivery Technologies 16%
• Chronic Respiratory Infection 16%
• Antibiotic-free 16%
• Persisters 16%
• Dormant Bacteria 16%
• Drug Tolerance 16%
• Antibiotic Adjuvant 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Antibiotic Agent 50%
• Respiratory Tract Infection 33%
• Disease 16%
• Antibiotics 16%
• Adjuvant 16%
• Antimicrobial Therapy 16%
• Drug Tolerability 16%